Experimental Weight Loss Drug 'Rata' Sparks Global Frenzy Amid Safety Concerns
An experimental weight loss drug, known as 'Rata' or Retatrutide, is generating significant buzz worldwide, particularly on TikTok, due to its reported efficacy in causing substantial weight loss. Clinical trial data suggests participants lost an average of 28.3% of their body weight over 80 weeks. However, the drug is still in clinical development and has not yet been approved for commercial use by any regulatory authority, including the U.S. Food and Drug Administration (FDA).
Despite its unapproved status, Retatrutide is being openly sold and discussed online, with individuals documenting dramatic physical transformations and even offering it for sale. This has led to a proliferation of counterfeit versions originating from countries like the U.S., China, and India. These illicit versions pose serious health risks, as evidenced by a recent case in Australia where an individual was hospitalized with severe, uncontrollable vomiting, later found to be caused by a fake product that did not contain Retatrutide.
Retatrutide is a synthetic peptide designed to activate three hormonal pathways in the body: GLP-1 (also found in Ozempic and Wegovy), GIP (found in Mounjaro), and glucagon. This triple action is believed to enhance its weight loss effects by influencing satiety, food intake, and metabolism. Eli Lilly, the pharmaceutical company developing the original Retatrutide, has reported positive Phase 3 trial results and plans to submit an application for FDA approval in early 2027.
Health authorities, including the FDA and Israel's Ministry of Health, are warning the public about the dangers of purchasing unapproved and potentially counterfeit drugs online. The Ministry of Health has detected products claiming to contain Retatrutide through customs inspections and is awaiting lab results to determine if public warnings are necessary. They emphasize that the drug is not approved for human use in Israel or globally and that any claims of it being for 'research use only' do not permit its import, marketing, or sale. The Ministry strongly advises purchasing medications only through authorized channels like pharmacies and drugstores, and avoiding social media and unknown websites.
The unregulated online market for such drugs is expanding rapidly alongside the legitimate obesity treatment market, which has seen the introduction of new pills and the development of next-generation combination therapies. Eli Lilly has stated that they do not market or sell Retatrutide for patient use, as it remains an investigational drug.
